SPRINGFIELD, Ill. (WCIA) — Faith and community leaders gathered in Springfield on Wednesday to call for increased oversight ...

The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more claims data on dispensed 340B drugs is onerous and unlawful.

The 340B program spent $43.9 billion in 2021, supporting nearly 50,000 hospitals with discounted outpatient drugs. Cancer drugs constitute 41% of 340B purchases, with outpatient departments and ...

On February 2, 2024, the “gang of six”—a bipartisan group of six senators who have traditionally championed reforms to the 340B program 1 —introduced a discussion draft of a bill that would modify the ...

Senator calls on Congress to increase oversight of the 340B Drug Pricing Program by requiring participating providers to complete annual reports on program savings and revenues. If your health system ...

In a move that will fundamentally change how the 340B Drug Pricing Program (“340B Program”) operates for a subset of medications, HRSA’s Office of Pharmacy Affairs (“OPA”) opted late last week to ...

The drug discount program is under scrutiny on a variety of fronts ...

The 340B Drug Pricing Program was developed more than three decades ago to help improve access to medicines for vulnerable patients 4 via manufacturer discounts to specific nonprofit hospitals and ...

Congress needs to act to bring needed reforms into the 340B to make revenue from the drug pricing program more transparent and to ensure patients are benefiting from the discounts, according to a ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

Amid ongoing controversy over 340B drug discounts, a sweeping review suggests the program is doing what it was intended to do: generate revenue for hospitals, clinics and pharmacies by requiring ...

Evolving trends in prostate cancer: Disparities across income levels and global regions (1990-2019). This is an ASCO Meeting Abstract from the 2024 ASCO Genitourinary Cancers Symposium. This abstract ...